Program
SCT650C
A development code.
Its studies are mostly in Hidradenitis Suppurativa · Axial Spondyloarthritis · Autoimmune Diseases, led by Sinocelltech Group.
Furthest: phase 2, since Dec 11, 20233 company-led studies, 3 open or runningNext primary completion: Mar 12, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinocelltech Group | 33 open or running | phase 2since Dec 11, 2023 | May 29, 2023 | Mar 12, 2027phase 2 · NCT07244510 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 29, 2023First study: phase 1 study in Autoimmune DiseasesFirst studyNCT05894707 · 32 planned · Australia
- Dec 11, 2023Phase 2 study in Axial SpondyloarthritisNCT06197009 · 168 planned · Turkey
- Nov 17, 2025Phase 2 study in Hidradenitis SuppurativaNCT07244510 · 60 planned · Turkey (Türkiye)
Ahead
- Mar 12, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07244510
TargetBeta
IL17A →read by rule
“SCT650C is a novel humanized monoclonal antibody against human IL-17A developed by Sinocelltech which is now on the first step of clinical evaluation.”study text, by rule · the study
Other programs on IL17A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| secukinumabrule | Novartis | phase 4 | 128 |
| ixekizumabrule | Eli Lilly | phase 4 | 38 |
| vunakizumabrule | Jiangsu HengRui Medicine | phase 4 | 17 |
| bimekizumabrule | UCB | phase 3 | 43 |
| sonelokimabrule | moonlake-immunotherapeutics-ag | phase 3 | 12 |
| tibulizumabrule | Eli Lilly | phase 2 | 5 |
| UA026rule | usynova-pharmaceuticals-ltd | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07244510Hidradenitis Suppurativa · Turkey (Türkiye) | 2 | Recruiting | Mar 12, 2027 | 60 |
| NCT06197009Axial Spondyloarthritis · Turkey | 2 | Not yet recruiting | Jul 1, 2026 | 168 |
| NCT05894707Autoimmune Diseases · Australia | 1 | Not yet recruiting | Nov 2023 | 32 |
How it is read
Names in the registry
- “SCT650C”, 3 entries
Codes read as this program: SCT650C.
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 1 study
- Axial Spondyloarthritis, 1 study
- Autoimmune Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.